1. Lomustine with or without reirradiation for first progression of glioblastoma, LEGATO, EORTC-2227-BTG: study protocol for a randomized phase III study.
- Author
-
Preusser M, Kazda T, Le Rhun E, Sahm F, Smits M, Gempt J, Koekkoek JA, Monti AF, Csanadi M, Pitter JG, Bulbek H, Fournier B, Quoilin C, Gorlia T, Weller M, and Minniti G
- Subjects
- Humans, Quality of Life, Randomized Controlled Trials as Topic, Chemoradiotherapy methods, Clinical Trials, Phase III as Topic, Pragmatic Clinical Trials as Topic, Time Factors, Glioblastoma pathology, Glioblastoma drug therapy, Glioblastoma mortality, Glioblastoma radiotherapy, Glioblastoma therapy, Lomustine administration & dosage, Lomustine therapeutic use, Lomustine adverse effects, Brain Neoplasms radiotherapy, Brain Neoplasms pathology, Brain Neoplasms mortality, Brain Neoplasms therapy, Disease Progression, Antineoplastic Agents, Alkylating therapeutic use, Multicenter Studies as Topic, Progression-Free Survival
- Abstract
Background: Chemotherapy with lomustine is widely considered as standard treatment option for progressive glioblastoma. The value of adding radiotherapy to second-line chemotherapy is not known., Methods: EORTC-2227-BTG (LEGATO, NCT05904119) is an investigator-initiated, pragmatic (PRECIS-2 score: 34 out of 45), randomized, multicenter phase III trial in patients with first progression of glioblastoma. A total of 411 patients will be randomized in a 1:1 ratio to lomustine (110 mg/m
2 every 6 weeks) or lomustine (110 mg/m2 every 6weeks) plus radiotherapy (35 Gy in 10 fractions). Main eligibility criteria include histologic confirmation of glioblastoma, isocitrate dehydrogenase gene (IDH) wild-type per WHO 2021 classification, first progression at least 6 months after the end of prior radiotherapy, radiologically measurable disease according to RANO criteria with a maximum tumor diameter of 5 cm, and WHO performance status of 0-2. The primary efficacy endpoint is overall survival (OS) and secondary endpoints include progression-free survival, response rate, neurocognitive function, health-related quality of life, and health economic parameters. LEGATO is funded by the European Union's Horizon Europe Research program, was activated in March 2024 and will enroll patients in 43 sites in 11 countries across Europe with study completion projected in 2028., Discussion: EORTC-2227-BTG (LEGATO) is a publicly funded pragmatic phase III trial designed to clarify the efficacy of adding reirradiation to chemotherapy with lomustine for the treatment of patients with first progression of glioblastoma., Trial Registration: ClinicalTrials.gov NCT05904119. Registered before start of inclusion, 23 May 2023., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF